Advertisement
Australia markets close in 1 hour 22 minutes

  • ALL ORDS

    7,851.80
    -85.70 (-1.08%)
     

  • ASX 200

    7,590.30
    -92.70 (-1.21%)
     

  • AUD/USD

    0.6527
    +0.0004 (+0.06%)
     

  • OIL

    83.86
    +0.29 (+0.35%)
     

  • GOLD

    2,346.70
    +4.20 (+0.18%)
     

  • Bitcoin AUD

    98,528.45
    -5.71 (-0.01%)
     

  • CMC Crypto 200

    1,387.11
    +4.54 (+0.33%)
     

  • AUD/EUR

    0.6086
    +0.0012 (+0.20%)
     

  • AUD/NZD

    1.0957
    -0.0001 (-0.01%)
     

  • NZX 50

    11,813.91
    -132.52 (-1.11%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    17,917.28
    -171.42 (-0.95%)
     

  • Hang Seng

    17,626.75
    +342.21 (+1.98%)
     

  • NIKKEI 225

    38,018.65
    +390.17 (+1.04%)
     

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2020 Financial Results on August 11, 2020

Vir Biotechnology, Inc.
·1-min read

SAN FRANCISCO, July 28, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that it will provide a corporate update and report financial results for the second quarter ended June 30, 2020 on Tuesday, August 11, 2020.

The update will be provided via a press release after market close, and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio.

About Vir Biotechnology

Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting hepatitis B virus, influenza A, SARS-CoV-2, human immunodeficiency virus and tuberculosis.

ADVERTISEMENT
CONTACT: Contact: Investors Neera Ravindran, M.D. VP, Head of Investor Relations & Strategic Communications nravindran@vir.bio +1-415-506-5256 Media Julie Normart W2O Group jnormart@w2ogroup.com +1-559-974-3245